Evidence map›Paper›PMID 34075436›Full record

ReviewDiabetologia2021

Youth-onset type 2 diabetes: translating epidemiology into clinical trials.

Laura Pyle, Megan M Kelsey

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Laura PyleSection of Paediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
Megan M KelseySection of Paediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA. megan.kelsey@childrenscolorado.org.

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
NICHD NIH HHS K12 HD057022NIDDK NIH HHS R01 DK111604NIDDK NIH HHS R01 DK119450NIDDK NIH HHS U01 DK061230
6 · The paper itself

Abstract

Globally, the proportion of new diagnoses of youth-onset diabetes represented by type 2 diabetes is increasing, and youth with type 2 diabetes commonly have complications and comorbidities, as well as a higher rate of mortality. In this review, we summarise what is known about the natural progression of youth-onset type 2 diabetes from published clinical trials and large-scale prospective epidemiological studies. It is important to note that the robust pathophysiological and treatment data specifically related to individuals with a diabetes onset at ≤20 years of age largely hails from the USA. Youth-onset type 2 diabetes is characterised by pathophysiological heterogeneity and inadequate glycaemic control, highlighting the need for new treatment approaches and innovative study designs in populations of varied genetic and cultural backgrounds.

Indexed as

Clinical Trials as TopicTranslational Science, BiomedicalAdolescentChildDiabetes Mellitus, Type 2FemaleGlycemic ControlHumansHypoglycemic AgentsInsulinLife StyleMaleMetforminProspective StudiesRosiglitazoneYoung AdultHypoglycemic AgentsInsulinMetforminRosiglitazoneClinical trialsEpidemiological studiesReviewStudy designYouth-onset type 2 diabetes

Identifiers

PMID34075436

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.